PLAT and ischemic stroke: Biomechanistic understanding of tPA’s fibrinolytic function led to the development of recombinant tPA (rtPA) as a thrombolytic agent, and the current standard of care for moderate to severe ischemic stroke is thrombolytic therapy with rtPA (Prabhakaran et al., 2015).